Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07828236) titled 'PHASE 1 TRIAL OF Lm-LLO-TT AND GEMCITABINE IN UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA' on Sept. 14.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Loki Therapeutics, Inc.
Condition:
Pancreas Cancer, Duct Cell Adenocarcinoma
Pancreatic Cancer
Advanced Pancreatic Adenocarcinoma
Intervention:
Biological: Lm-LLO-TT
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: October 15, 2026
Target Sample Size: 18
Countries of Recruitment:
United ...